Apogee Therapeutics (APGE) Cash from Operations (2022 - 2026)
Apogee Therapeutics (APGE) reported Cash from Operations of 55570000.0 for Q1 2026, down 14.63% year-over-year from 65094405.81 in Q1 2025, and up 11.3% quarter-over-quarter from 62650000.0 in Q4 2025.
Apogee Therapeutics (APGE) Cash from Operations (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Cash from Operations data on file, last reported at 55570000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 55570000.0, down 14.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 234543000.0 (down 24.75% YoY), and the FY2025 annual result was 227450000.0, down 32.88% from the prior year.
- Cash from Operations improved to 55570000.0 in Q1 2026 per APGE's latest filing, from 62650000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 9189000.0 in Q4 2022 and troughed at 67714000.0 in Q4 2024.
- A 5-year average of 38438857.14 and a median of 37080000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations tumbled 223.8% in 2023, then rose 7.48% in 2025.
- A 5-year view of Cash from Operations shows it stood at 9189000.0 in 2022, then plunged by 223.8% to 29754000.0 in 2023, then slumped by 127.58% to 67714000.0 in 2024, then climbed by 7.48% to 62650000.0 in 2025, then increased by 11.3% to 55570000.0 in 2026.
- Business Quant data shows APGE's Cash from Operations at 55570000.0 in Q1 2026, 62650000.0 in Q4 2025, and 54294000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | -55.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.57 Mn |
| Mar 31, 2026 | -55.57 Mn |
| Dec 31, 2025 | -62.65 Mn |
| Dec 31, 2025 | -62.65 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Jun 30, 2025 | -62.03 Mn |
| Jun 30, 2025 | -62.03 Mn |
| Mar 31, 2025 | -48.48 Mn |
| Mar 31, 2025 | -48.48 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Sep 30, 2024 | -42.52 Mn |
| Sep 30, 2024 | -42.52 Mn |
| Jun 30, 2024 | -29.30 Mn |
| Jun 30, 2024 | -29.30 Mn |
| Mar 31, 2024 | -31.64 Mn |
| Mar 31, 2024 | -31.64 Mn |
| Dec 31, 2023 | -29.75 Mn |
| Dec 31, 2023 | -29.75 Mn |